HSP90 targeted conjugates and particles and formulations thereof
Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
1. A particle comprising a conjugate, wherein the conjugate comprises an active agent coupled to a HSP90 targeting moiety by a linker, wherein the active agent is a topoisomerase I inhibitor and the HSP90 targeting moiety is a small molecule.
2. The particle of claim 1 , wherein the linker is not a cleavable linker.
3. The particle of claim 1 , wherein the linker is a cleavable linker.
4. The particle of claim 3 , wherein the linker comprises an ester bond, disulfide, amide, acylhydrazone, ether, carbamate, carbonate, or urea.
5. The particle of claim 1 , wherein the particle comprises at least one polymeric matrix.
6. The particle of claim 5 , wherein the polymeric matrix comprises one or more polymers selected from the group consisting of hydrophobic polymers, hydrophilic polymers, and copolymers thereof.
7. The particle of claim 6 , wherein the polymeric matrix comprises one or more polymers selected from the group consisting of poly(lactic acid) (PLA), poly(glycolic acid), poly(lactic-co-glycolic acid), and copolymers thereof.
8. The particle of claim 1 , wherein the polymeric matrix comprises two or more different polymers.
9. The particle of claim 8 , wherein the polymeric matrix comprises PEG and PLA.
10. The particle of claim 1 , wherein the conjugate is present in an amount between about 0.05% and about 50% (w/w) based upon the weight of the particle.
11. The particle of claim 10 , wherein the actual drug load (ADL) of the conjugate is at least about 5, about 6, about 7, about 8, about 9, or about 10 wt %.
12. The particle of claim 1 , wherein the encapsulation efficiency is at least about 90%, about 95%, or about 98%.
13. The particle of claim 1 , wherein the AUC of the conjugate in the particle is at least about 10, at least about 25, at least about 50, or at least about 100 fold more than the AUC of the free conjugate.
14. The particle of claim 1 , wherein the ratio of rate of plasma clearance (CL) of the free conjugate to CL of the conjugate in the particle is at least about 10, at least about 25, at least about 50, or at least about 100.
15. The particle of claim 1 , wherein the ratio of C max of the conjugate in the particle to C max of the free conjugate is at least about 2, at least about 4, at least about 5, or at least about 10.
16. The particle of claim 1 , wherein the ratio of t½ of the conjugate in the particle formulation to t½ of the free conjugate is at least about 2, at least about 4, or at least about 5.
17. A pharmaceutical formulation comprising the particle of claim 1 and at least one pharmaceutically acceptable excipient.
18. The particle of claim 1 , wherein the active agent is SN-38, irinotecan, or camptothecin.
19. The particle of claim 1 , wherein the HSP90 targeting moiety is ganetespib or a tautomer or a derivative thereof.